Skip to main content
Top
Published in: Medical Oncology 2/2012

01-06-2012 | Original Paper

MicroRNA-9 up-regulation is involved in colorectal cancer metastasis via promoting cell motility

Authors: Liang Zhu, Huarong Chen, Donger Zhou, Dan Li, Rui Bai, Shu Zheng, Weiting Ge

Published in: Medical Oncology | Issue 2/2012

Login to get access

Abstract

Human microRNA-9 (miR-9) has been reported to be involved in the metastasis of several malignancies including brain breast cancer. However, its role in the metastasis of colorectal cancer (CRC) remains to be revealed. Here, we evaluated miR-9 expression in metastatic CRC and investigated its effects on the motility and proliferation of RKO cells. The expressions of miR-9 in 15 primary CRC specimens without distant metastasis (NM group) and 10 primary CRC specimens (M group) with distant metastasis (M group) were determined by quantitative real-time PCR. The alternations in the motility and morphology of RKO cells before and after miR-9 transfection were analyzed by migration assay and F-actin staining. The relationship between miR-9 and α-catenin was identified by Western blotting. Cell growth was examined by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazoliumbromide) assay. Significant difference of miR-9 expression was observed in M group compared to the NM group (P < 0.001). Ectopic expression of miR-9 enhanced the motility of RKO cells as well as changed their morphological appearance, while cell growth remained unchanged. The overexpression of miR-9 could also down-regulate α-catenin expression. These data suggest that miR-9 may potentially participate in the metastatic process of CRC though facilitating cell motility.
Literature
1.
go back to reference Blumgart LH, Fong Y. Surgical options in the treatment of hepatic metastasis from colorectal cancer. Curr Probl Surg. 1995;32(5):333–421.PubMedCrossRef Blumgart LH, Fong Y. Surgical options in the treatment of hepatic metastasis from colorectal cancer. Curr Probl Surg. 1995;32(5):333–421.PubMedCrossRef
2.
go back to reference Newland RC, Dent OF, Chapuis PH, Bokey EL. Clinicopathologically diagnosed residual tumor after resection for colorectal cancer. A 20-year prospective study. Cancer. 1993;72(5):1536–42.PubMedCrossRef Newland RC, Dent OF, Chapuis PH, Bokey EL. Clinicopathologically diagnosed residual tumor after resection for colorectal cancer. A 20-year prospective study. Cancer. 1993;72(5):1536–42.PubMedCrossRef
3.
4.
go back to reference Ma L, Young J, Prabhala H, Pan E, Mestdagh P, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol. 2010;12(3):247–56.PubMed Ma L, Young J, Prabhala H, Pan E, Mestdagh P, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol. 2010;12(3):247–56.PubMed
5.
go back to reference Nass D, Rosenwald S, Meiri E, Gilad S, Tabibian-Keissar H, et al. MiR-92b and miR-9/9* are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors. Brain Pathol. 2009;19(3):375–83.PubMedCrossRef Nass D, Rosenwald S, Meiri E, Gilad S, Tabibian-Keissar H, et al. MiR-92b and miR-9/9* are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors. Brain Pathol. 2009;19(3):375–83.PubMedCrossRef
6.
go back to reference Zheng J, Xue H, Wang T, Jiang Y, Liu B, et al. miR-21 downregulates the tumor suppressor P12(CDK2AP1) and stimulates cell proliferation and invasion. J Cell Biochem. 2011;112(3):872–80.PubMedCrossRef Zheng J, Xue H, Wang T, Jiang Y, Liu B, et al. miR-21 downregulates the tumor suppressor P12(CDK2AP1) and stimulates cell proliferation and invasion. J Cell Biochem. 2011;112(3):872–80.PubMedCrossRef
7.
go back to reference Roybal JD, Zang Y, Ahn YH, Yang Y, Gibbons DL, et al. miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1. Mol Cancer Res. 2011;9(1):25–35.PubMedCrossRef Roybal JD, Zang Y, Ahn YH, Yang Y, Gibbons DL, et al. miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1. Mol Cancer Res. 2011;9(1):25–35.PubMedCrossRef
8.
go back to reference Fowler A, Thomson D, Giles K, Maleki S, Mreich E, et al. miR-124a is frequently down-regulated in glioblastoma and is involved in migration and invasion. Eur J Cancer. 2011;47(6):953–63.PubMedCrossRef Fowler A, Thomson D, Giles K, Maleki S, Mreich E, et al. miR-124a is frequently down-regulated in glioblastoma and is involved in migration and invasion. Eur J Cancer. 2011;47(6):953–63.PubMedCrossRef
9.
go back to reference Wu ZS, Wu Q, Wang CQ, Wang XN, Huang J, et al. miR-340 inhibition of breast cancer cell migration and invasion through targeting of oncoprotein c-Met. Cancer. 2011 [Epub ahead of print]. Wu ZS, Wu Q, Wang CQ, Wang XN, Huang J, et al. miR-340 inhibition of breast cancer cell migration and invasion through targeting of oncoprotein c-Met. Cancer. 2011 [Epub ahead of print].
10.
go back to reference Li X, Zhang Y, Shi Y, Dong G, Liang J, et al. MicroRNA-107, an oncogene MicroRNA that regulates tumor invasion and metastasis by targeting DICER1 in gastric cancer: MiR-107 promotes gastric cancer invasion and metastasis. J Cell Mol Med. 2011 [Epub ahead of print]. Li X, Zhang Y, Shi Y, Dong G, Liang J, et al. MicroRNA-107, an oncogene MicroRNA that regulates tumor invasion and metastasis by targeting DICER1 in gastric cancer: MiR-107 promotes gastric cancer invasion and metastasis. J Cell Mol Med. 2011 [Epub ahead of print].
11.
go back to reference Hurteau GJ, Carlson JA, Spivack SD, Brock GJ. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res. 2007;67(17):7972–6.PubMedCrossRef Hurteau GJ, Carlson JA, Spivack SD, Brock GJ. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res. 2007;67(17):7972–6.PubMedCrossRef
12.
go back to reference Christoffersen NR, Silahtaroglu A, Orom UA, Kauppinen S, Lund AH. miR-200b mediates post-transcriptional repression of ZFHX1B. RNA. 2007;13(8):1172–8.PubMedCrossRef Christoffersen NR, Silahtaroglu A, Orom UA, Kauppinen S, Lund AH. miR-200b mediates post-transcriptional repression of ZFHX1B. RNA. 2007;13(8):1172–8.PubMedCrossRef
13.
go back to reference Kong W, Yang H, He L, Zhao JJ, Coppola D, et al. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol. 2008;28(22):6773–84.PubMedCrossRef Kong W, Yang H, He L, Zhao JJ, Coppola D, et al. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol. 2008;28(22):6773–84.PubMedCrossRef
14.
go back to reference Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM, et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell. 2009;137(6):1032–46.PubMedCrossRef Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM, et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell. 2009;137(6):1032–46.PubMedCrossRef
15.
go back to reference Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449(7163):682–8.PubMedCrossRef Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449(7163):682–8.PubMedCrossRef
16.
go back to reference Packer AN, Xing Y, Harper SQ, Jones L, Davidson BL. The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington’s disease. J Neurosci. 2008;28(53):14341–6.PubMedCrossRef Packer AN, Xing Y, Harper SQ, Jones L, Davidson BL. The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington’s disease. J Neurosci. 2008;28(53):14341–6.PubMedCrossRef
17.
go back to reference Laneve P, Gioia U, Andriotto A, Moretti F, Bozzoni I, et al. A minicircuitry involving REST and CREB controls miR-9-2 expression during human neuronal differentiation. Nucleic Acids Res. 2010;38(20):6895–905.PubMedCrossRef Laneve P, Gioia U, Andriotto A, Moretti F, Bozzoni I, et al. A minicircuitry involving REST and CREB controls miR-9-2 expression during human neuronal differentiation. Nucleic Acids Res. 2010;38(20):6895–905.PubMedCrossRef
19.
go back to reference Breen E, Steele G Jr, Mercurio AM. Role of the E-cadherin/alpha-catenin complex in modulating cell–cell and cell–matrix adhesive properties of invasive colon carcinoma cells. Ann Surg Oncol. 1995;2(5):378–85.PubMedCrossRef Breen E, Steele G Jr, Mercurio AM. Role of the E-cadherin/alpha-catenin complex in modulating cell–cell and cell–matrix adhesive properties of invasive colon carcinoma cells. Ann Surg Oncol. 1995;2(5):378–85.PubMedCrossRef
20.
go back to reference Aberle H, Butz S, Stappert J, Weissig H, Kemler R, et al. Assembly of the cadherin-catenin complex in vitro with recombinant proteins. J Cell Sci. 1994;107(Pt 12):3655–63.PubMed Aberle H, Butz S, Stappert J, Weissig H, Kemler R, et al. Assembly of the cadherin-catenin complex in vitro with recombinant proteins. J Cell Sci. 1994;107(Pt 12):3655–63.PubMed
21.
go back to reference Rimm DL, Koslov ER, Kebriaei P, Cianci CD, Morrow JS. Alpha 1(E)-catenin is an actin-binding and -bundling protein mediating the attachment of F-actin to the membrane adhesion complex. Proc Natl Acad Sci USA. 1995;92(19):8813–7.PubMedCrossRef Rimm DL, Koslov ER, Kebriaei P, Cianci CD, Morrow JS. Alpha 1(E)-catenin is an actin-binding and -bundling protein mediating the attachment of F-actin to the membrane adhesion complex. Proc Natl Acad Sci USA. 1995;92(19):8813–7.PubMedCrossRef
22.
go back to reference Pappas DJ, Rimm DL. Direct interaction of the C-terminal domain of alpha-catenin and F-actin is necessary for stabilized cell-cell adhesion. Cell Commun Adhes. 2006;13(3):151–70.PubMedCrossRef Pappas DJ, Rimm DL. Direct interaction of the C-terminal domain of alpha-catenin and F-actin is necessary for stabilized cell-cell adhesion. Cell Commun Adhes. 2006;13(3):151–70.PubMedCrossRef
23.
go back to reference Gofuku J, Shiozaki H, Tsujinaka T, Inoue M, Tamura S, et al. Expression of E-cadherin and alpha-catenin in patients with colorectal carcinoma. Correlation with cancer invasion and metastasis. Am J Clin Pathol. 1999;111(1):29–37.PubMed Gofuku J, Shiozaki H, Tsujinaka T, Inoue M, Tamura S, et al. Expression of E-cadherin and alpha-catenin in patients with colorectal carcinoma. Correlation with cancer invasion and metastasis. Am J Clin Pathol. 1999;111(1):29–37.PubMed
24.
go back to reference Kitagawa T, Matsumoto K, Nagafuchi A, Tsukita S, Suzuki H. Co-expression of E-cadherin and alpha-catenin molecules in colorectal cancer. Surg Today. 1999;29(6):511–8.PubMedCrossRef Kitagawa T, Matsumoto K, Nagafuchi A, Tsukita S, Suzuki H. Co-expression of E-cadherin and alpha-catenin molecules in colorectal cancer. Surg Today. 1999;29(6):511–8.PubMedCrossRef
25.
go back to reference Raftopoulos I, Davaris P, Karatzas G, Karayannacos P, Kouraklis G. Level of alpha-catenin expression in colorectal cancer correlates with invasiveness, metastatic potential, and survival. J Surg Oncol. 1998;68(2):92–9.PubMedCrossRef Raftopoulos I, Davaris P, Karatzas G, Karayannacos P, Kouraklis G. Level of alpha-catenin expression in colorectal cancer correlates with invasiveness, metastatic potential, and survival. J Surg Oncol. 1998;68(2):92–9.PubMedCrossRef
26.
go back to reference Drees F, Pokutta S, Yamada S, Nelson WJ, Weis WI. Alpha-catenin is a molecular switch that binds E-cadherin-beta-catenin and regulates actin-filament assembly. Cell. 2005;123(5):903–15.PubMedCrossRef Drees F, Pokutta S, Yamada S, Nelson WJ, Weis WI. Alpha-catenin is a molecular switch that binds E-cadherin-beta-catenin and regulates actin-filament assembly. Cell. 2005;123(5):903–15.PubMedCrossRef
Metadata
Title
MicroRNA-9 up-regulation is involved in colorectal cancer metastasis via promoting cell motility
Authors
Liang Zhu
Huarong Chen
Donger Zhou
Dan Li
Rui Bai
Shu Zheng
Weiting Ge
Publication date
01-06-2012
Publisher
Springer US
Published in
Medical Oncology / Issue 2/2012
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-9975-z

Other articles of this Issue 2/2012

Medical Oncology 2/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.